Skip to main content

Children’s Healthcare of Atlanta (CHOA) is the first hospital in Georgia to implant the reSept ASD Occluder in patients with atrial septal defects (ASD) as part of the ASCENT ASD study.

Interventional cardiologist Dr. Dennis Kim led the team that conducted the intervention to successfully seal a child’s ASD for the first time in Georgia. Dr. Kim is Director of the Pediatric Cardiac Catheterization Labs at CHOA Heart Center. He specializes in interventional procedures and minimally invasive treatments for congenital heart disease and is involved in a variety of clinical trials for new transcatheter device therapies, including ASCENT ASD. ASCENT ASD is an FDA-approved research study currently enrolling patients in over 20 centers across 18 States in the USA.

“Our team is excited to contribute to research that may advance the treatment for ASDs by leaving a minimal footprint in a child’s heart,” said Dr Kim. “The reSept device is a game changer due to its bioresorbable properties and represents true innovation in implantable cardiac device therapy.

atHeart Medical’s reSept ASD Occluder is the first transcatheter septal occluder with a metal-free frame. Occluders currently available have a metal frame that remains in the patient’s heart for life.

“We are grateful to Dr. Kim and to the extraordinary clinicians that have joined ASCENT ASD, for their commitment to improve ASD treatment, and to patients and their parents for their trust in research,” said atHeart Medical CEO Laurent Grandidier. “Our device has been developed with a life’s journey in mind, with a heart that has less metal and a more natural septum profile.”

An atrial septal defect is a hole in the heart wall called septum that separates two heart chambers. ASDs are among the most common heart defects children may be born with. They can be treated with an occluder through minimally invasive surgery in most patients. Please follow the link for further information on ASDs.